Angelini To Commercialize ARIAD's Iclusig In Central And Eastern Europe

(RTTNews) - ARIAD Pharmaceuticals Inc. (ARIA) and Angelini Pharma, through the Austrian subsidiary CSC Pharmaceuticals, announced that ARIAD has granted Angelini exclusive rights to commercialize Iclusig (ponatinib) for the indications approved by the European Medicine Agency in Central and Eastern Europe. The countries include Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia. With the new distributorship, Iclusig will be available to patients in more than 23 countries in Europe.

An upfront payment to ARIAD and milestones associated with commercial launches will total approximately $7.3 million. Angelini will provide ARIAD with a substantial share of Iclusig sales in the region.

Angelini is a privately-held, mid-sized international manufacturer and marketer of pharmaceutical and healthcare products in the pharmaceutical and mass-market sectors.